Πλοήγηση ανά Συγγραφέα "Papandreou, C. N."
Αποτελέσματα 1-20 από 31
-
Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer
(2014)We studied tissue mRNA levels of VEGF-Axxxa angiogenic versus VEGF-Axxxb anti-angiogenic isoforms by means of specially designed PCR assays in two parallel cohorts of metastatic breast cancer patients, one treated with ... -
Baseline Insulin-Like Growth Factor-I Plasma Levels, Systemic Inflammation, Weight Loss and Clinical Outcome in Metastatic Non-Small Cell Lung Cancer Patients
(2011)Background: Cancer patients frequently suffer from weight loss and systemic inflammation in the context of advanced disease, which is related to adverse outcome. Insulin-like growth factor (IGF)-I is an anabolic molecule ... -
The Bmi-1/NF-kappa B/VEGF story: another hint for proteasome involvement in glioma angiogenesis?
(2013)Angiogenesis is an essential process for sustaining tumor growth, particularly in cancer cell types with rapid proliferation, including malignant glioma. Bmi-1 is a transcriptional regulator of the polycomb group involved ... -
Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells
(2013)The efficacy of treatment for glioblastoma multiforme is currently limited by the development of resistance, particularly, but not exclusively, due to the expression of the DNA repair enzyme O6-methylguanine methyltransferase ... -
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
(2013)Development of drug resistance after standard chemotherapy for glioblastoma multiforme (GBM) with temozolomide (TMZ) is associated with poor prognosis of GBM patients and is at least partially mediated by a direct DNA ... -
Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
(2012)Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown ... -
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells
(2012)Objectives: Neuropeptides are important signal initiators in advanced prostate cancer, partially acting through activation of nuclear factor kappa B. Central to nuclear factor kappa B regulation is the ubiquitin-proteasome ... -
CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy
(2012)Introduction: The cell surface endopeptidase CD10 (neutral endopeptidase) and nuclear factor-kappa B (NF-kappa B) have been independently associated with prostate cancer (PC) progression. We investigated the correlations ... -
Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in "thin" and "thick" tissue sections
(2012)One presumed drawback of performing fluorescence in situ hybridization on routine tissue sections for HER-2 status evaluation in breast carcinomas is nuclear truncation. Therefore, HER-2/CEP 17 ratios were compared in ... -
CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases
(2013)CUZD1, the CUB, and zona pellucida-like domains-containing protein 1, is a newly identified antigen of pancreatic autoantibodies (PAB) giving a reticulogranular pattern in patients with inflammatory bowel diseases, and in ... -
Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer; A Phase II Study From The Hellenic Cooperative Oncology Group
(2014)Aim: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). Patients and Methods: Patients were ... -
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
(2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ... -
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis
(2015)Introduction: Maximizing responses of malignant gliomas is hampered by resistance to temozolomide (TMZ). Increasing efficacy but not toxicity is a key issue when testing drug combinations. The antimyeloma agent bortezomib ... -
Evidence of Association Between Methylenetetrahydrofolate Reductase Gene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population
(2012)The methylenetetrahydrofolate reductase (MTHFR) gene has been proposed as a candidate gene for breast cancer (BC). However, the specific role of MTHFR polymorphisms and haplotypes has not been fully clarified and replicated. ... -
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma
(2013)The 26S proteasome constitutes an essential degradation apparatus involved in the consistent recycling of misfolded and damaged proteins inside cells. The aberrant activation of the proteasome has been widely observed in ... -
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NF kappa B and mutant p53
(2013)The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma resistance to alkylating agents. Several strategies have been used to induce sensitization to alkylator-based treatments, ...